Nektar Therapeutics (NKTR)
Nektar Therapeutics Statistics
Share Statistics
Nektar Therapeutics has 186.1M shares outstanding. The number of shares has increased by 1.13% in one year.
| Shares Outstanding | 186.1M |
| Shares Change (YoY) | 1.13% |
| Shares Change (QoQ) | 0.89% |
| Owned by Institutions (%) | 63.51% |
| Shares Floating | 179.37M |
| Failed to Deliver (FTD) Shares | 365.76K |
| FTD / Avg. Volume | 15.39% |
Short Selling Information
The latest short interest is 6.62M, so 3.56% of the outstanding shares have been sold short.
| Short Interest | 6.62M |
| Short % of Shares Out | 3.56% |
| Short % of Float | 3.69% |
| Short Ratio (days to cover) | 3.08 |
Valuation Ratios
The PE ratio is -1.61 and the forward PE ratio is -0.92. Nektar Therapeutics's PEG ratio is 0.03.
| PE Ratio | -1.61 |
| Forward PE | -0.92 |
| PS Ratio | 1.94 |
| Forward PS | 0.7 |
| PB Ratio | 3.15 |
| P/FCF Ratio | -1.08 |
| PEG Ratio | 0.03 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Nektar Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.26, with a Debt / Equity ratio of 1.69.
| Current Ratio | 4.26 |
| Quick Ratio | 4.26 |
| Debt / Equity | 1.69 |
| Debt / EBITDA | -1.18 |
| Debt / FCF | -0.58 |
| Interest Coverage | -3.74 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $1.61M |
| Profits Per Employee | $-1.95M |
| Employee Count | 61 |
| Asset Turnover | 0.32 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -239K |
| Effective Tax Rate | 0.2% |
Stock Price Statistics
The stock price has increased by -57.72% in the last 52 weeks. The beta is 0.69, so Nektar Therapeutics's price volatility has been higher than the market average.
| Beta | 0.69 |
| 52-Week Price Change | -57.72% |
| 50-Day Moving Average | 0.78 |
| 200-Day Moving Average | 1.08 |
| Relative Strength Index (RSI) | 44.73 |
| Average Volume (20 Days) | 2.38M |
Income Statement
In the last 12 months, Nektar Therapeutics had revenue of 98.43M and earned -118.96M in profits. Earnings per share was -0.58.
| Revenue | 98.43M |
| Gross Profit | 67.74M |
| Operating Income | -105.2M |
| Net Income | -118.96M |
| EBITDA | -86.7M |
| EBIT | -91.09M |
| Earnings Per Share (EPS) | -0.58 |
Balance Sheet
The company has 44.25M in cash and 102.56M in debt, giving a net cash position of -58.31M.
| Cash & Cash Equivalents | 44.25M |
| Total Debt | 102.56M |
| Net Cash | -58.31M |
| Retained Earnings | -3.6B |
| Total Assets | 303.85M |
| Working Capital | 199.89M |
Cash Flow
In the last 12 months, operating cash flow was -175.71M and capital expenditures -1.47M, giving a free cash flow of -177.18M.
| Operating Cash Flow | -175.71M |
| Capital Expenditures | -1.47M |
| Free Cash Flow | -177.18M |
| FCF Per Share | -0.86 |
Margins
Gross margin is 68.82%, with operating and profit margins of -106.88% and -120.86%.
| Gross Margin | 68.82% |
| Operating Margin | -106.88% |
| Pretax Margin | -121.1% |
| Profit Margin | -120.86% |
| EBITDA Margin | -88.08% |
| EBIT Margin | -106.88% |
| FCF Margin | -180.01% |
Dividends & Yields
NKTR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for NKTR is $5, which is 693.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $5 |
| Price Target Difference | 693.7% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Stock Splits
The last stock split was on Aug 23, 2000. It was a forward split with a ratio of 2:1.
| Last Split Date | Aug 23, 2000 |
| Split Type | forward |
| Split Ratio | 2:1 |
Scores
| Altman Z-Score | -16.21 |
| Piotroski F-Score | 2 |